Opdivo
The researchers found biomarkers of macrophage activity and immune activity were associated with resistance and response to Opdivo plus Cabometyx.
BMS Seeking FDA Approval for Opdivo-Yervoy in Frontline MSI-High, dMMR Advanced Colorectal Cancer
The firm submitted data from a Phase III study showing the combination improved outcomes compared to Opdivo and chemo alone.
Intravenous Opdivo, with $2.48 billion in sales, topped the list of precision oncology products in BMS's growth portfolio.
Opdivo, Yervoy Outperform Single-Agent Immunotherapy in First-Line MSI-High, dMMR Colorectal Cancer
Premium
Data presented at the ASCO Gastrointestinal Cancers Symposium showed the regimen may be a new option, but it comes with more treatment and financial toxicity.
BMS third quarter revenues increased 8 percent to $11.90 billion, with its growth portfolio now making up half of total revenues.
Jul 26, 2024
Apr 25, 2024